Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety

Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Piramal Pharma Solutions supports George Medicines in developing new drug for hypertension

WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals

Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site

The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities

Piramal Pharma releases Sustainability Report FY 2023-24

The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

Piramal Pharma Solutions commissions ADC manufacturing expansion in Scotland

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant

Piramal Pharma starts production at new API facility in Riverview, Michigan

New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)

Piramal Pharma strengthens board by inducting three new board members

The appointments will add to the well-diversified experience that currently exists on the PPL board.

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E